{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Langford CA"],"funding":["Bristol-Myers Squibb","NCRR NIH HHS","NIAMS NIH HHS","NIH HHS"],"pubmed_abstract":["<h4>Objective</h4>To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA).<h4>Methods</h4>In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or equivalent), tapered and discontinued at week 12. Patients already taking methotrexate, azathioprine, mycophenolate, or leflunomide continued this medication at a stable dose. Patients achieving remission remained on their randomized assignment until relapse, early termination, or the common close date 12 months after enrollment of the last patient. Those who had a nonsevere relapse, had nonsevere worsening, or were not in remissio"],"journal":["Arthritis & rheumatology (Hoboken, N.J.)"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12413890"],"repository":["biostudies-literature"],"pubmed_title":["A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis."],"pmcid":["PMC12413890"],"funding_grant_id":["U54 AR057319","U54 RR019497","IM101-446","U01 AR5187404"],"pubmed_authors":["Williams L","Lienesch D","Bakaj E","Zhang M","Siegwald E","Conway R","Jeon A","Dehghan N","Penmetsa G","Leon M","Pradere MJ","Jin M","Stewart B","Liang K","Daley S","Moreland LW","Forbess LJ","Hall J","Ziemek J","Strozniak L","Robins D","Brickell K","Thapa D","Fifi-Mah A","Mieras K","Gonzalez J","Cuthbertson D","Ishimori M","Martins K","Rice B","Sandhu N","Clark T","Hellmich B","Gonzalez B","Williams S","Amdemicael B","Springer J","Yu N","Burroughs C","Specks U","Baqir M","Donlinger S","Langford CA","Matara C","Peikert T","Thomas A","Negrey J","Draper P","Howard T","Bernardo M","Fatis S","Thompson GE","Ghetie D","Shojania K","Bath A","Finco M","Kempiners N","Warrington KJ","Venuturupalli S","Koslow M","Kirchheim MK","Gaucher S","Yacyshyn E","Jayaraman J","Gallagher P","Pagnoux C","Flossmann O","Butler A","Jagadeesh S","Quinn R","Fernandez A","Krischer JP","Lally L","Kim Y","Messier S","Bloostein A","Haq N","MacDonald M","Madden L","Gewurz-Singer O","Zammitti C","Koening CL","Chakravorty M","Clifford A","Mohan N","Glasco L","Carter J","Dahlsveen K","Paul B","Olmos B","Weisman M","Hope L","Ache J","Wiecek A","Sylvester J","Sreih A","Molloy E","Beinhorn C","Hollinger N","Chaudary S","Lin YC","Reckley K","Aggarwal B","Trojanowski M","Wallace D","Mahrhofer H","Friedman M","Jones RB","Hildebrand A","Lewis E","Chu CQ","Lewis G","Orzechowski M","Khurana S","Alexander R","McMillian C","de Tenorio AR","Lanyon P","Hatzis C","Gartner K","Thome H","Gopaluni S","Hajj-Ali R","Godina J","Stachowitz M","Vasculitis Clinical Research Consortium and the European Vasculitis Society","Kisela E","Rhee RL","Ortez N","Crook S","Spiera R","Tusty M","Vendramini J","McCune WJ","Sibley C","Rutter M","Walz B","Peel K","McAlear CA","Stratton E","McClure M","Godsave C","Amudala N","Merkel PA","Thompson S","Khalidi N","Jayne D","Kado R","Carette S","Smith R","Nguyen KP","Joseph M","Monach PA","Koster MJ","Bork D","Doyle K"],"additional_accession":[]},"is_claimable":false,"name":"A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis.","description":"<h4>Objective</h4>To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA).<h4>Methods</h4>In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or equivalent), tapered and discontinued at week 12. Patients already taking methotrexate, azathioprine, mycophenolate, or leflunomide continued this medication at a stable dose. Patients achieving remission remained on their randomized assignment until relapse, early termination, or the common close date 12 months after enrollment of the last patient. Those who had a nonsevere relapse, had nonsevere worsening, or were not in remissio","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-06-02T22:37:29.463Z","creation":"2026-04-21T03:13:21.969Z"},"accession":"S-EPMC12413890","cross_references":{"pubmed":["40506793"],"doi":["10.1002/art.43272"]}}